Goldman Sachs 10th Annual Healthcare CEOs Unscripted,Thursday, January 4 , at3:15 p.m. ET at the InterContinental,Boston, Massachusetts .-
36th Annual
J.P. Morgan Healthcare Conference ,Tuesday, January 9 , at7:30 a.m. PT , followed by Q&A, at theWestin St. Francis Hotel ,San Francisco, California .
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the event.
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio's gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin®
product candidate, currently in five clinical studies for the treatment
of transfusion-dependent β-thalassemia, also known as β-thalassemia
major, and severe sickle cell disease. bluebird bio's oncology pipeline
is built upon the company's leadership in lentiviral gene delivery and T
cell engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T cell
receptor (TCR) therapies. bluebird bio's lead oncology programs, bb2121
and bb21217, are anti-BCMA CAR T programs partnered with Celgene. bb2121
and bb21217 are each currently being studied in Phase 1 trials for the
treatment of relapsed/refractory multiple myeloma. bluebird bio also has
discovery research programs utilizing megaTALs/homing endonuclease gene
editing technologies with the potential for use across the company's
pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, Durham, North Carolina and Europe.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, risks that the
current or planned clinical trials of the LentiGlobin drug product will
be insufficient to support regulatory submissions or marketing approval
in the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221006025/en/
Source: bluebird bio, Inc.
Investors & Media
bluebird bio
Elizabeth Pingpank,
617-914-8736
epingpank@bluebirdbio.com